K2 Principal Fund, L.P. Adverum Biotechnologies, Inc. Transaction History

K2 Principal Fund, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $89,480 - $902,263	-93,209 Reduced 89.97%	10,391 $10,000
Q2 2022 Aug 12, 2022	SELL	$0.81 - $1.34 $135,514 - $224,184	-167,302 Reduced 61.76%	103,600 $124,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $184,551 - $292,581	-150,042 Reduced 35.64%	270,902 $355,000
Q4 2021 Feb 11, 2022	SELL	$1.74 - $2.4 $2.15 Million - $2.96 Million	-1,232,930 Reduced 74.55%	420,944 $741,000
Q3 2021 Nov 12, 2021	BUY	$2.08 - $3.6 $1.57 Million - $2.72 Million	755,567 Added 84.11%	1,653,874 $3.59 Million
Q2 2021 Aug 13, 2021	BUY	$3.36 - $10.56 $3.02 Million - $9.49 Million	898,307 New	898,307 $3.14 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of K2 Principal Fund, L.P., based on Form 13F filings with the SEC.

Stay updated on K2 Principal Fund, L.P. with notifications on news.